Overview

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

Status:
Completed
Trial end date:
2020-11-30
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Apremilast
BMS-986165
Criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Plaque psoriasis for at least 6 months

- Moderate to severe disease

- Candidate for phototherapy or systemic therapy

Exclusion Criteria:

- Other forms of psoriasis

- History of recent infection

- Prior exposure to BMS-986165 or active comparator

Other protocol defined inclusion/exclusion criteria could apply